Investigational drug · Phase 2
CMTX-101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Persistent Infection, Cystic Fibrosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "CMTX-101"
First trial start
2024
Jun 24, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CMTX-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Persistent Infection
- Cystic Fibrosis
Approved drugs for the same conditions: Cystic fibrosis · Infectious disease and vaccines · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "CMTX-101" as an intervention, largest first.
Clarametyx Biosciences, Inc.Industry
NCT06159725 · 43 participants · Start Jun 24, 2024 · Primary completion Nov 14, 2025
Drug: CMTX-101; Placebo · For: Persistent Infection; Cystic Fibrosis
Sites: Birmingham, Alabama; Palo Alto, California; San Franciso, California · 23 sites in all
Clarametyx Biosciences, Inc.Industry
NCT05629741 · 28 participants · Start Nov 14, 2022 · Primary completion Aug 2, 2024
Drug: CMTX-101; Placebo · For: Community-acquired Pneumonia; Bacterial Pneumonia
Sites: Augusta, Georgia; Idaho Falls, Idaho; Louisville, Kentucky · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Antibiotics and non-traditional antimicrobial agents for carbapenem-resistant Acinetobacter baumannii in Phase 1, 2, and 3 clinical trials.
Kontogiannis DS, Romanos LT, Tzvetanova ID, et al. · Expert Opin Investig Drugs 2025
- Antibiotics and non-traditional antimicrobial agents for Pseudomonas aeruginosa in clinical phases 1, 2, and 3 trials.
Romanos LT, Kontogiannis DS, Tsiampali C, et al. · Expert Opin Investig Drugs 2025
- Crumbling the Castle: Targeting DNABII Proteins for Collapsing Bacterial Biofilms as a Therapeutic Approach to Treat Disease and Combat Antimicrobial Resistance.
Rogers JV, Hall VL, McOsker CC · Antibiotics (Basel) 2022
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.